Intra-Cellular Therapies, Inc. (ITCI)
Largest Insider Buys in Sector
ITCI Stock Price History Chart
ITCI Stock Performance
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Activity of Intra-Cellular Therapies, Inc.
Over the last 12 months, insiders at Intra-Cellular Therapies, Inc. have bought $0 and sold $55.93M worth of Intra-Cellular Therapies, Inc. stock.
On average, over the past 5 years, insiders at Intra-Cellular Therapies, Inc. have bought $8.09M and sold $30.93M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 99,000 shares for transaction amount of $2.93M was made by Alafi Christopher D (director) on 2020‑09‑14.
List of Insider Buy and Sell Transactions, Intra-Cellular Therapies, Inc.
| 2024-06-24 | Sale | RIGGS RORY B | director | 4,462 0.0042% | $75.57 | $337,193 | -4.17% | |
| 2024-06-18 | Sale | VAN NOSTRAND ROBERT L | director | 20,000 0.0208% | $75.91 | $1.52M | +0.11% | |
| 2024-03-11 | Sale | Mates Sharon | Chairman, President & CEO | 20,565 0.0212% | $65.21 | $1.34M | +3.80% | |
| 2024-03-11 | Sale | Neumann Mark | EVP, Chief Commercial Officer | 7,345 0.0076% | $65.61 | $481,931 | +3.80% | |
| 2024-03-11 | Sale | Durgam Suresh K. | EVP, Chief Medical Officer | 3,712 0.0038% | $65.59 | $243,482 | +3.80% | |
| 2024-03-11 | Sale | Hineline Lawrence J. | SVP of Finance, CFO | 10,121 0.0105% | $65.96 | $667,587 | +3.80% | |
| 2024-03-11 | Sale | Halstead Michael | EVP and General Counsel | 7,345 0.0076% | $65.97 | $484,537 | +3.80% | |
| 2024-03-07 | Sale | Mates Sharon | Chairman, President & CEO | 40,712 0.0419% | $66.50 | $2.71M | +1.83% | |
| 2024-03-07 | Sale | Neumann Mark | EVP, Chief Commercial Officer | 13,132 0.0135% | $66.57 | $874,179 | +1.83% | |
| 2024-03-07 | Sale | Durgam Suresh K. | EVP, Chief Medical Officer | 6,450 0.0066% | $66.56 | $429,308 | +1.83% | |
| 2024-03-07 | Sale | Hineline Lawrence J. | SVP of Finance, CFO | 13,132 0.0135% | $66.60 | $874,560 | +1.83% | |
| 2024-03-07 | Sale | Halstead Michael | EVP and General Counsel | 13,132 0.0134% | $66.15 | $868,698 | +1.83% | |
| 2024-02-27 | Sale | VAN NOSTRAND ROBERT L | director | 20,000 0.0206% | $72.93 | $1.46M | -6.84% | |
| 2024-02-26 | Sale | Mates Sharon | Chairman, President & CEO | 22,590 0.0228% | $69.79 | $1.58M | -5.04% | |
| 2024-02-26 | Sale | MARCUS JOEL S | director | 26,328 0.0261% | $68.68 | $1.81M | -5.04% | |
| 2024-02-26 | Sale | Neumann Mark | EVP, Chief Commercial Officer | 7,907 0.008% | $70.13 | $554,491 | -5.04% | |
| 2024-02-26 | Sale | Durgam Suresh K. | EVP, Chief Medical Officer | 4,112 0.0042% | $70.17 | $288,534 | -5.04% | |
| 2024-02-26 | Sale | Hineline Lawrence J. | SVP of Finance, CFO | 13,337 0.0134% | $69.43 | $925,961 | -5.04% | |
| 2024-02-26 | Sale | Halstead Michael | EVP and General Counsel | 7,907 0.0079% | $69.53 | $549,784 | -5.04% | |
| 2024-02-02 | Sale | Mates Sharon | Chairman, President & CEO | 33,885 0.0345% | $67.07 | $2.27M | +1.75% |
Insider Historical Profitability
| Mates Sharon | Chairman, President & CEO | 1050309 1.0914% | $71.09 | 0 | 37 | |
| RIGGS RORY B | 116600 0.214% | $71.09 | 2 | 2 | +11.52% | |
| Neumann Mark | EVP, Chief Commercial Officer | 29700 0.0309% | $71.09 | 0 | 21 | |
| MARCUS JOEL S | director | 39662 0.0304% | $71.09 | 0 | 16 | |
| VAN NOSTRAND ROBERT L | director | 9690 0.0097% | $71.09 | 1 | 4 | +35.53% |
| Durgam Suresh K. | EVP, Chief Medical Officer | 19803 0.0059% | $71.09 | 0 | 17 | |
| Halstead Michael | EVP and General Counsel | 0 0% | $71.09 | 2 | 29 | +67.15% |
| Hineline Lawrence J. | SVP of Finance, CFO | 0 0% | $71.09 | 0 | 40 | |
| ALAFI MOSHE | 10 percent owner | 3953270 4.1078% | $71.09 | 12 | 1 | +49.4% |
| ALAFI CAPITAL CO LLC | 10 percent owner | 3953270 4.1078% | $71.09 | 12 | 0 | +49.4% |
| Sosland Morton I. | 10 percent owner | 2198554 2.2845% | $71.09 | 1 | 0 | +24.33% |
| Fienberg Allen A. | VP of Business Development | 197823 0.2056% | $71.09 | 0 | 3 | |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 126500 0.1314% | $71.09 | 0 | 10 | |
| Alafi Christopher D | director | 95000 0.0987% | $71.09 | 22 | 4 | +43.73% |
| LERNER RICHARD A | director | 93813 0.0975% | $71.09 | 1 | 2 | +35.53% |
| Davis Robert E | SVP, Chief Scientific Officer | 43989 0.0457% | $71.09 | 0 | 5 | |
| Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 27068 0.0281% | $71.09 | 0 | 7 | |
| Satlin Andrew | EVP and Chief Medical Officer | 11338 0.0118% | $71.09 | 0 | 1 |
Institutional Investor Ownership
| Fidelity Investments | $774.67M | 10.6 | 11.19M | -2.3% | -$18.21M | 0.05 | |
| The Vanguard Group | $638.44M | 8.74 | 9.23M | +1.45% | +$9.11M | 0.01 | |
| BlackRock | $558.98M | 7.65 | 8.08M | -1.41% | -$8.01M | 0.01 | |
| Wasatch Advisors | $266.75M | 3.65 | 3.85M | +6.27% | +$15.74M | 1.4 | |
| Bellevue Group | $195.11M | 2.67 | 2.82M | -8.05% | -$17.09M | 2.98 | |
| Avoro Capital Advisors Llc | $171.27M | 2.34 | 2.48M | +9.73% | +$15.19M | 2.05 | |
| State Street | $155.06M | 2.12 | 2.24M | +0.89% | +$1.37M | 0.01 | |
| Invesco | $143.45M | 1.96 | 2.07M | +5.57% | +$7.57M | 0.03 | |
| Geode Capital Management | $142.94M | 1.96 | 2.07M | +3.17% | +$4.4M | 0.01 | |
| JPMorgan Chase | $121.51M | 1.66 | 1.76M | -15.28% | -$21.91M | 0.01 | |
| ClearBridge Investments | $120.72M | 1.65 | 1.74M | +12.32% | +$13.25M | 0.1 | |
| Wellington Management Company | $115M | 1.57 | 1.66M | -5.76% | -$7.03M | 0.02 | |
| Franklin Templeton Investments | $112.07M | 1.53 | 1.62M | -9.02% | -$11.11M | 0.03 | |
| GW&K Investment Management | $110.65M | 1.52 | 1.6M | -1.8% | -$2.03M | 0.98 | |
| AllianceBernstein | $109.39M | 1.5 | 1.58M | -12.28% | -$15.31M | 0.04 | |
| Deep Track Capital Lp | $103.8M | 1.42 | 1.5M | -25% | -$34.6M | 0.48 | |
| Macquarie Group | $101.2M | 1.39 | 1.46M | -6.51% | -$7.04M | 0.08 | |
| T. Rowe Price | $83.32M | 1.14 | 1.2M | -4.51% | -$3.94M | 0.01 | |
| Perceptive Advisors | $73.03M | 1 | 1.06M | +877.18% | +$65.56M | 0.05 | |
| Charles Schwab | $69.6M | 0.95 | 1.01M | +1.21% | +$832,821.99 | 0.02 | |
| Suvretta Capital Management, LLC | $66.38M | 0.91 | 959,198 | -17.73% | -$14.31M | 2.8 | |
| Morgan Stanley | $65.03M | 0.89 | 939,797 | -24.33% | -$20.91M | 0.01 | |
| Holocene Advisors, LP | $62.91M | 0.86 | 909,090 | -27.96% | -$24.41M | 0.23 | |
| Northern Trust | $60.76M | 0.83 | 877,992 | -5% | -$3.2M | 0.01 | |
| Nuveen | $56.72M | 0.78 | 819,675 | -6.96% | -$4.25M | 0.02 | |
| Goldman Sachs | $53.04M | 0.73 | 766,427 | +32.46% | +$13M | 0.01 | |
| First Trust | $47.79M | 0.65 | 690,637 | +6,279.43% | +$47.04M | 0.05 | |
| Assenagon Asset Management S.A. | $44.97M | 0.62 | 649,817 | -14.94% | -$7.9M | 0.12 | |
| Schroder Investment Management Group | $42.79M | 0.59 | 618,388 | -20.7% | -$11.17M | 0.05 | |
| Avidity Partners Management Lp | $41.52M | 0.57 | 600,000 | -15.49% | -$7.61M | 1.51 | |
| Deutsche Bank | $40.96M | 0.56 | 591,889 | -6.18% | -$2.7M | 0.02 | |
| Bank of America | $38.91M | 0.53 | 562,325 | +16.35% | +$5.47M | <0.01 | |
| Adage Capital Partners Gp L L C | $38.75M | 0.53 | 560,000 | +103.64% | +$19.72M | 0.07 | |
| American Century Investments | $37.57M | 0.51 | 542,913 | +13.05% | +$4.34M | 0.02 | |
| Lord Abbett | $32.71M | 0.45 | 472,687 | -38.85% | -$20.78M | 0.11 | |
| Ameriprise Financial | $28.52M | 0.39 | 412,196 | +295.63% | +$21.31M | 0.01 | |
| Balyasny Asset Management Llc | $28.42M | 0.39 | 410,634 | +32.47% | +$6.96M | 0.08 | |
| Janus Henderson | $27.77M | 0.38 | 401,357 | -17.95% | -$6.07M | 0.02 | |
| Emerald Advisers, Inc. | $27.79M | 0.38 | 401,611 | +16.81% | +$4M | 1.13 | |
| D. E. Shaw & Co. | $27.01M | 0.37 | 390,279 | -23.71% | -$8.39M | 0.04 | |
| TimesSquare Capital Management LLC | $26.52M | 0.36 | 383,211 | -22.79% | -$7.83M | 0.39 | |
| BNY Mellon | $26.04M | 0.36 | 376,271 | -9.39% | -$2.7M | 0.01 | |
| Citadel Advisors LLC | $25M | 0.34 | 361,294 | +915.67% | +$22.54M | 0.02 | |
| HERITAGE ASSET MANAGEMENT INC | $24.05M | 0.33 | 352,342 | -19.14% | -$5.69M | 0.12 | |
| Bank of Montreal | $23.25M | 0.32 | 333,455 | -0.38% | -$87,625.47 | 0.01 | |
| EMERALD MUTUAL FUND ADVISERS TRUST | $21.6M | 0.3 | 312,131 | +11.24% | +$2.18M | 1.14 | |
| Millennium Management LLC | $19.57M | 0.27 | 282,744 | -24.3% | -$6.28M | 0.01 | |
| Caption Management Llc | $18.46M | 0.25 | 266,780 | +567% | +$15.69M | 0.58 | |
| General American Investors | $18.02M | 0.25 | 260,439 | 0% | +$0 | 1.34 | |
| Alyeska Investment Group L P | $17.43M | 0.24 | 251,920 | +112.08% | +$9.21M | 0.11 |